Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
ACHIEVE LIFE SCIENCES, INC. incurred term loan of aggregate original principal amount of $16.56 million with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P., as lenders at floating rate per annum equal to the greater of (i) 2.25% and (ii) the prime rat maturing December 22, 2024, subject to acceleration upon failure to receive FDA filing communication by certain dates.
- Instrument
- term loan
- Principal
- aggregate original principal amount of $16.56 million
- Counterparty
- Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P., as lenders
- Rate
- floating rate per annum equal to the greater of (i) 2.25% and (ii) the prime rat
- Maturity
- December 22, 2024, subject to acceleration upon failure to receive FDA filing communication by certain dates
- Event
- incurrence
Exact text from the filing
On May 15, 2023, Achieve Life Sciences, Inc. (“ Achieve ”) entered into a contingent convertible debt agreement (the “ Debt Agreement ”) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“ FCB ”), in its capacity as administrative agent and collateral agent (in such capacity, the “ Agent ”), FCB, as a lender, SVB Innovation Credit Fund VIII, L.P., as a lender (“ Innovation ”), and Innovation Credit Fund VIII-A, L.P., as a lender (together with FCB and Innovation, the “ Lenders ”), pursuant to which the Lenders provided term loans having an aggregate original principal amount of $16.56 million (the “ Convertible Term Loan ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ACHIEVE LIFE SCIENCES, INC. entered into Debt Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and the Lenders (SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P.) valued at $16.56 million (effective 2023-05-15).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and the Lenders (SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P.)
- Value
- $16.56 million
- Effective
- 2023-05-15
Exact text from the filing
On May 15, 2023, Achieve Life Sciences, Inc. (“ Achieve ”) entered into a contingent convertible debt agreement (the “ Debt Agreement ”) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“ FCB ”), in its capacity as administrative agent and collateral agent (in such capacity, the “ Agent ”), FCB, as a lender, SVB Innovation Credit Fund VIII, L.P., as a lender (“ Innovation ”), and Innovation Credit Fund VIII-A, L.P., as a lender (together with FCB and Innovation, the “ Lenders ”), pursuant to which the Lenders provided term loans having an aggregate original principal amount of $16.56 million (the “ Convertible Term Loan ”).
View on SEC.gov